Advertisement
Screener

SYNLOGIC, INC. (SYBX) Increase (Decrease) in Deferred Liabilities

2.8 / 5 stars · 68/120 Roast Me

SYNLOGIC, INC. Increase (Decrease) in Deferred Liabilities

SYNLOGIC, INC. (SYBX) reported Increase (Decrease) in Deferred Liabilities of $1.27 million for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-12.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredLiabilities · last filed 2020-03-12

  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-12-31 was -$90.00K.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-09-30 was $269.00K.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-06-30 was $800.00K.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for the quarter ending 2018-03-31 was $295.00K.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for fiscal 2018 was $1.27M.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for fiscal 2017 was -$1.12M, a 5438.10% decline from fiscal 2016.
  • SYNLOGIC, INC. increase (decrease) in deferred liabilities for fiscal 2016 was $21.00K.
Period endIncrease (Decrease) in Deferred Liabilities 3 monthIncrease (Decrease) in Deferred Liabilities 6 monthIncrease (Decrease) in Deferred Liabilities 9 monthIncrease (Decrease) in Deferred Liabilities 12 month
2018-12-31-$90.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$179.00K
derived: sum of 2 quarters · filed 2020-03-12
$979.00K
derived: sum of 3 quarters · filed 2020-03-12
$1.27M
10-K · filed 2020-03-12
2018-09-30$269.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12
$1.07M
derived: sum of 2 quarters · filed 2019-11-12
$1.36M
10-Q · filed 2019-11-12
$781.00K
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$800.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$1.09M
10-Q · filed 2019-08-08
$512.00K
derived: sum of 3 quarters · filed 2019-08-08
$101.00K
derived: sum of 4 quarters · filed 2019-08-08
2018-03-31$295.00K
10-Q · filed 2019-05-09
-$288.00K
derived: sum of 2 quarters · filed 2019-05-09
-$699.00K
derived: sum of 3 quarters · filed 2019-05-09
-$763.00K
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31-$583.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12
-$994.00K
derived: sum of 2 quarters · filed 2019-03-12
-$1.06M
derived: sum of 3 quarters · filed 2019-03-12
-$1.12M
10-K · filed 2019-03-12
2017-09-30-$411.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13
-$475.00K
derived: sum of 2 quarters · filed 2018-11-13
-$538.00K
10-Q · filed 2018-11-13
-$594.00K
derived: sum of 4 quarters · filed 2018-11-13
2017-06-30-$64.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
-$127.00K
10-Q · filed 2018-08-09
-$183.00K
derived: sum of 3 quarters · filed 2018-08-09
2017-03-31-$63.00K
10-Q · filed 2018-05-15
-$119.00K
derived: sum of 2 quarters · filed 2018-05-15
2016-12-31-$56.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20
$21.00K
10-K · filed 2018-03-20
2016-09-30$77.00K
10-Q · filed 2017-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B
Apimeds Pharmaceuticals US, Inc. (APUS)United States$0.008B
InMed Pharmaceuticals Inc. (INM)$0.008B-0.65
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
Ensysce Biosciences, Inc. (ENSC)United States$0.008B-0.37
Pulmatrix, Inc. (PULM)United States$0.006B
EXICURE, INC. (XCUR)United States$0.008B-1.54